Filtered By:
Condition: Cholesterol

This page shows you your search results in order of date.

Order by Relevance | Date

Total 572 results found since Jan 2013.

GSE241894 Comparison of biochemical pathways affected by treatment with 4-methylumbelliferone and siRNA mediated knock down reveals hyaluronan synthase type 2 as a key pharmacological target in liver fibrosis
Contributors : Noreen Halimani ; Mikhail Nesterchuk ; Alexandra A Tsitrina ; Marat Sabirov ; Irina N Andreichenko ; Nataliya O Dashenkova ; Alexey M Kulikov ; Timofei S Zatsepin ; Roman A Romanov ; Arsen S Mikaelyan ; Yuri V KotelevtsevSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusHepatic fibrosis is a morbid pathology with unmet medical need. 4- methylumbelliferone (4-MU), an inhibitor of hyaluronan (HA) synthesis was shown to be safe in phase one clinical trials. To support drug development, it is essential to decipher 4-MU ’s pharmacological targets. Here, we compared the effec...
Source: GEO: Gene Expression Omnibus - August 31, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research

Musashi-2 binds with Fbxo6 to induce Rnaset2 ubiquitination and chemokine signaling pathway during vascular smooth muscle cell phenotypic switch in atherosclerosis
CONCLUSION: Our findings demonstrated that MSI2 could bind with Fbxo6 to induce Rnaset2 ubiquitination and the activation of chemokine signaling pathway during VSMC phenotypic switch in AS.PMID:37633478 | DOI:10.1016/j.cellsig.2023.110869
Source: Cellular Signalling - August 26, 2023 Category: Cytology Authors: Tao Zhang Shusheng Wu Rongwei Xu Shuguang Zhang Minghai Wang Jie Li Source Type: research

GSE233807 RNA N6-methyladenosine methyltransferase METTL3 drives NAFLD-HCC and is a therapeutic target for boosting immunotherapy m6A-seq
Series Type : Methylation profiling by high throughput sequencingOrganism : Homo sapiensNon-alcoholic fatty liver disease (NAFLD) is an emerging risk factor of hepatocellular carcinoma (HCC). However, the mechanism and target therapy on NAFLD-HCC are still unclear. Here, we identify that the N6-methyladenosine (m6A) methyltransferase METTL3 promotes NAFLD-HCC. Hepatocyte-specific Mettl3 knockin exacerbated NAFLD-HCC formation while Mettl3 knockout exerted an opposite effect in mice. Single-cell RNA-seq revealed that METTL3 suppressed antitumor immune response by reducing infiltration of Gzmb+ and IFN- γ+ CD8+ T-cell, ther...
Source: GEO: Gene Expression Omnibus - August 23, 2023 Category: Genetics & Stem Cells Tags: Methylation profiling by high throughput sequencing Homo sapiens Source Type: research

GSE233806 RNA N6-methyladenosine methyltransferase METTL3 drives NAFLD-HCC and is a therapeutic target for boosting immunotherapy RNA-Seq
Series Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensNon-alcoholic fatty liver disease (NAFLD) is an emerging risk factor of hepatocellular carcinoma (HCC). However, the mechanism and target therapy on NAFLD-HCC are still unclear. Here, we identify that the N6-methyladenosine (m6A) methyltransferase METTL3 promotes NAFLD-HCC. Hepatocyte-specific Mettl3 knockin exacerbated NAFLD-HCC formation while Mettl3 knockout exerted an opposite effect in mice. Single-cell RNA-seq revealed that METTL3 suppressed antitumor immune response by reducing infiltration of Gzmb+ and IFN- γ+ CD8+ T-cell, there...
Source: GEO: Gene Expression Omnibus - August 23, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Reduction in LDL-C following treatment with inclisiran at 2 months in a single centre lipid clinic cohort
Background and Aims: Inclisiran is a new first in class small interfering RNA (siRNA) lipid lowering drug that has been shown to be effective in reducing low-density lipoprotein cholesterol (LDL-c) in randomised controlled trials. However, real-world data of its use is currently lacking. We aimed to analyse the early effects of this drug in a tertiary centre lipid clinic.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: P. Padam, L. Barton, S. Wilson, A. David, S. Walji, F. De Lorenzo, K. Ray, B. Jones, J. Cegla Source Type: research

Estimating the potential impact of LDL-C lowering through SIRNA therapies on population health: A simulation study
Background and Aims: Inclisiran, an siRNA therapy, provides sustained reductions in LDL-C. Potential CV benefits of inclisiran, as an adjunct to statins, were evaluated through simulation.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: K. Ray, L. Gunn, L.G. Conde, F. Raal, R.S. Wright, N. Gosselin, L. Leiter, W. Koenig, G. Schwartz, U. Landmesser Source Type: research

The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies
Clin Ther. 2023 Jul 29:S0149-2918(23)00258-8. doi: 10.1016/j.clinthera.2023.07.008. Online ahead of print.ABSTRACTPURPOSE: High plasma concentrations of LDL and lipoprotein(a) (Lp[a]) are independent and causal risk factors for atherosclerotic cardiovascular disease (ASCVD). There is an unmet therapeutic need for high-risk patients with elevated levels of LDL-C and/or Lp(a). Recent advances in the development of nucleic acids for gene silencing (ie, triantennary N-acetylgalactosamine conjugated antisense-oligonucleotides [ASOs] and small interfering RNA [siRNA]) targeting proprotein convertase subtilisin/kexin type 9 (PCSK...
Source: Clinical Therapeutics - July 31, 2023 Category: Drugs & Pharmacology Authors: Dick C Chan Gerald F Watts Source Type: research

Lipid nanoparticle delivery of siRNA targeting < em > Cyp2e1 < /em > gene attenuates subacute alcoholic liver injury in mice
CONCLUSIONS: The si-Cyp2e1 LNP may attenuate subacute alcoholic liver injury in mice mainly by reducing reactive oxygen levels, increasing antioxidant activity, blocking oxidative stress pathways and reducing ethanol-induced steatosis and inflammation.PMID:37476942 | DOI:10.3724/zdxbyxb-2022-0729
Source: Cancer Control - July 21, 2023 Category: Cancer & Oncology Authors: Shuang Wu Qiubing Chen Yalan Wang Hao Yin Yuan Wei Source Type: research

Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies
AbstractLipoprotein(a), or Lp(a), is structurally like low-density lipoprotein (LDL) but differs in that it contains glycoprotein apolipoprotein(a) [apo(a)]. Due to its prothrombotic and proinflammatory properties, Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis. Lp(a) levels are genetically determined, and it is estimated that 20-25% of the global population has an Lp(a) level ≥50 mg/dL (or ≥125 nmol/L). Diet and lifestyle interventions have little to no effect on Lp(a) levels. Lipoprotein apheresis is the only approved treatment for elevated Lp(a) but i...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 19, 2023 Category: Drugs & Pharmacology Authors: Ibrahim S. Alhomoud, Azita Talasaz, Anurag Mehta, Michael Kelly, Evan M. Sisson, John D. Bucheit, Roy Brown, Dave L. Dixon Tags: REVIEW Source Type: research

Simvastatin prevents BMP-2 driven cell migration and invasion by suppressing oncogenic DNMT1 expression in breast cancer cells
This study emphasized to decipher the molecular mechanism of endogenous regulation of DNMT1 expression for finding upstream signaling molecules. Cancer database analyses found an upregulated DNMT1 expression in most cancer types including breast cancer. Overexpression of DNMT1 showed an increased cell migration, invasion, and stemness potential whereas 5-azacytidine (DNMT1 inhibitor) and siRNA mediated knockdown of DNMT1 exhibited inhibition of such cancer activities in breast cancer MDA-MB-231 and MCF-7 cells. Infact, cancer database analyses further found a positive correlation of DNMT1 transcript with both cholesterol p...
Source: Gene - July 13, 2023 Category: Genetics & Stem Cells Authors: Pooja Yadav Shreetama Bandyopadhayaya Sneha Soni Sunil Saini Lokendra K Sharma Sandeep K Shrivastava Chandi C Manda Source Type: research